1 Min Read
April 18 (Reuters) - AstraZeneca PLC:
* US FDA APPROVES TAGRISSO AS 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CANCER Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.